NCT03387111 2024-08-05
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
ImmunityBio, Inc.
Phase 1/2 Terminated
Clinical Trials
9 trialsNCT02438995 2021-11-03
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
Northwell Health
Phase 1 Terminated
NCT01133678 2020-05-08
Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck
University of Chicago
Phase 2 Terminated
NCT01871311 2019-02-08
A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors
Georgetown University
Phase 1 Terminated
NCT02205398 2019-01-22
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
Novartis
Phase 1 Terminated
NCT02633800 2019-01-07
Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
Daiichi Sankyo
Phase 2 Terminated
NCT00591149 2017-06-14
Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer
University of Kansas Medical Center
Phase 2 Terminated
NCT01794845 2017-05-11
Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma
University of Miami
Phase 2 Terminated
NCT01142869 2017-05-08
An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Merck KGaA, Darmstadt, Germany
Terminated